Avanir Pharmaceuticals, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Avanir Pharmaceuticals, Inc. (NASDAQ GS: AVNR) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Avanir Pharmaceuticals, Inc. (“Avanir” or the “Company”) (NASDAQ GS: AVNR) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), in a transaction valued at approximately $3.5 billion.

Under the terms of the proposal, public shareholders of Avanir would receive $17.00 per share in cash for each share of Avanir they own.

The investigation concerns whether Avanir’s board of directors failed to adequately shop the Company and obtain the best possible value for Avanir’s shareholders before entering into an agreement with Otsuka.  According to Yahoo! Finance, at least one analyst has issued a price target for Avanir stock at $21.00 per share.

If you own the common stock of Avanir and purchased your shares before December 2, 2014, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, Delaware 19803; by telephone at (888) 969-4242; or by e-mail to

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.